Last $2,908 MXN
Change Today -58.87 / -1.98%
Volume 306.0
As of 4:09 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN*) Snapshot

Open
$2,967
Previous Close
$2,967
Day High
$2,967
Day Low
$2,908
52 Week High
02/20/15 - $3,025
52 Week Low
04/22/14 - $1,901
Market Cap
418.1B
Average Volume 10 Days
1.6K
EPS TTM
--
Shares Outstanding
143.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILMN*)

illumina inc (ILMN*) Details

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,700 Employees
Last Reported Date: 02/18/15
Founded in 1998

illumina inc (ILMN*) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $235.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILMN*) Key Developments

Illumina Launches the NeoPrep Library Prep System

Illumina Inc. announced the launch of the NeoPrep Library Prep System, which greatly simplifies library preparation and delivers high-quality sequencing-ready libraries for next-generation sequencing (NGS). The newest addition to the Illumina portfolio of NGS solutions consists of a NeoPrep desktop instrument, disposable library cards, and reagents. Together with Illumina sequencers and the BaseSpace computing environment, the new system plays an integral role in providing NGS users with the easiest, most efficient and complete workflow. The NeoPrep System is the first commercially available product that performs library prep, quantification and normalization, in a single, self-contained instrument. Innovative digital microfluidics technology decreases hands-on time from several hours to 30 minutes. By precisely manipulating droplets within the tightly controlled library card environment, the system delivers reliable, high-quality DNA and RNA libraries from starting amounts 4 to 10 times lower than those required for equivalent manual assays. By creating 16 libraries per run, users can prepare up to 160 libraries per week, providing an affordable, walk-away solution that simplifies lab processes, and reduces the need for ancillary equipment and user-supplied reagents and consumables. The NeoPrep System is designed for use with the Illumina portfolio of library preparation kits, supporting the most commonly used NGS applications on all Illumina sequencing systems. Each kit includes the library card as well as all reagents required to create NeoPrep libraries. The NeoPrep System and NeoPrep versions of the TruSeq Nano DNA Kit and TruSeq Stranded mRNA Kit will begin shipping in March 2015. Additional library preparation products will become available later in the year, including NeoPrep versions of the TruSeq DNA PCR-Free Kit and other targeted resequencing kits.

Illumina, Inc. Announces Retirement of Gerald Möller as Member of its Board of Directors

On January 29, 2015, Dr. Gerald Möller announced the board of directors of Illumina Inc. that he will retire as a member of the board of directors, effective immediately before the company’s 2015 annual meeting of stockholders.

Illumina Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2014; Provides Earnings Guidance for the Full Year of Fiscal 2015; Provides Tax Rate Guidance for the First Quarter of 2015

Illumina Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 28, 2014. For the quarter, the company announced total revenue of $512,379,000 compared to $387,326,000 for the same period a year ago. Income from operations was $202,883,000 compared to $73,784,000 for the same period a year ago. Income before income taxes was $192,061,000 compared to $120,369,000 for the same period a year ago. Net income was $153,280,000 compared to $80,661,000 for the same period a year ago. Net income per diluted share was $1.03 compared to $0.56 for the same period a year ago. Net cash provided by operating activities was $140,549,000 compared to $126,839,000 for the same period a year ago. Purchases of property and equipment were $34,832,000 compared to $27,310,000 for the same period a year ago. Free cash flow was $105,717,000 compared to $99,529,000 for the same period a year ago. Non-GAAP net income per share, diluted was $0.87 compared to $0.45 for the same period a year ago. Non-GAAP net income was $128,949,000 compared to $64,504,000 for the same period a year ago. Non-GAAP operating profit was $192,990,000 compared to $124,918,000 for the same period a year ago. Capital expenditures were $35 million, resulting in $106 million of free cash flow. For the full year, the company announced total revenue of $1,861,358,000 compared to $1,421,178,000 for the same period a year ago. Income from operations was $514,711,000 compared to $134,107,000 for the same period a year ago. Income before income taxes was $448,758,000 compared to $159,314,000 for the same period a year ago. Net income was $353,351,000 compared to $125,308,000 for the same period a year ago. Net income per diluted share was $2.37 compared to $0.90 for the same period a year ago. Net cash provided by operating activities was $501,271,000 compared to $386,421,000 for the same period a year ago. Purchases of property and equipment were $105,996,000 compared to $79,215,000 for the same period a year ago. Free cash flow was $395,275,000 compared to $307,206,000 for the same period a year ago. Non-GAAP net income per share, diluted was $2.74 compared to $1.80 for the same period a year ago. Non-GAAP net income was $407,217,000 compared to $249,663,000 for the same period a year ago. Non-GAAP operating profit was $686,275,000 compared to $462,229,000 for the same period a year ago. The company provided earnings guidance for the full year of fiscal 2015. For the fiscal 2015, the company is projecting approximately 20% revenue growth, assuming current currency exchange rates, and non-GAAP earnings per diluted share of $3.12 to $3.18. These projections assume full year non-GAAP gross margin of approximately 73%, and a pro forma tax rate of approximately 28%. The company also expects to report GAAP gross margin of 70.5% and GAAP diluted net income per share between $2.73 and $2.79. The company expects the first quarter of 2015 tax rate of approximately 29%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN*:MM $2,907.63 MXN -58.87

ILMN* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $129.02 USD +1.40
Dr Reddy's Laboratories Ltd 3,400 INR +13.50
Sigma-Aldrich Corp $138.07 USD +0.01
Symrise AG €56.70 EUR +0.027
Waters Corp $121.36 USD +0.98
View Industry Companies
 

Industry Analysis

ILMN*

Industry Average

Valuation ILMN* Industry Range
Price/Earnings 82.4x
Price/Sales 14.9x
Price/Book 19.2x
Price/Cash Flow 71.6x
TEV/Sales 13.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.